Day: August 10, 2023

– First patient dosed in Phase 1b/2a clinical trial of AJ201; topline data anticipated in first half of 2024 – – Positive BAER-101 preclinical data demonstrate excellent anti-seizure activity in translational animal model; Phase 2a trial in epilepsy planned to initiate in 2024 – – Agreement reached with U.S. FDA on study design and analysis approach for Phase 3 safety study of IV tramadol – MIAMI, Aug. 10, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2023. “Avenue continues to make significant progress across...

Presented positive INB-200 Phase 1 data in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting showing 100% of treated patients (n=8) have exceeded historical median progression-free survival INB-400 on track to initiate enrollment in glioblastoma multiforme (GBM) in the second half of 2023. The Phase 2 trial (NCT05664243) will initially enroll newly diagnosed GBM patients in the autologous setting. The primary endpoint of the study is overall survival (OS); secondary endpoints include tolerability, progression-free survival (PFS), overall response rate (ORR) and time to progression (TTP) Promising preclinical data in ovarian cancer announced at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting underscores the synergistic potential of DeltEx gamma-delta T cells and chemotherapy...

Second Quarter Revenues Were $37.8 million and Gross Margin Expanded to 53% Year-to-Date Net Loss Attributable to UpHealth, Inc. Improved 9% to $27.2 million Year-to-Date Adjusted EBITDA Improved by $9.2 million to $11.8 million Closed Strategic Sale of Innovations Group, Inc. for $56.0 million Completed Repurchase of $10.3 Million of Convertible Debt Increasing Full Year 2023 Outlook DELRAY BEACH, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) — UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the second quarter ended June 30, 2023. UpHealth Chief Executive Officer Sam Meckey said, “During the second quarter we delivered results I am very proud of...

Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022 Signed FIND R&D collaboration contract extension Entered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S. Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ETROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. Second...

Management forecasts to reach gross margin positive in Q3 2023Term sheet executed with lead investor for up to $150 million secured debt facility Q2 2023 Financial HighlightsRevenue Growth: Q2’23 revenue of $28 million grew 72% year-over-year compared to $16 million in Q2’22. Gross Margin Improvement: Higher quality revenue, lower fixed costs, improved factory efficiencies, favorable mix, and product cost reductions all drove improving margins y/y:Gross loss improved from ($23 million) in Q2’22 to ($14 million) in Q2’23.Reduction in Operating Expenses: 2022 and 2023 cost reductions resulted in:R&D expense declined by 54% y/y from Q2’22 to Q2’23. SG&A expense declined by 42% y/y from Q2’22 to Q2’23.Continued Progress to Profitability: Revenue growth, improving gross margins, and lower operating expense resulted in:Loss...

Q3’23 Revenue Increased 22% to $14.7M with 2nd Consecutive Quarter of Positive Operating Income of $0.1M Gross Margin up 200 Basis Points to 44% in Q3’23 Management to Host Conference Call Today at 5:00 p.m. ET Brooklyn, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) —  – Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its financial and operational results for the third quarter ended June 30, 2023. Key Third Quarter FY 2023 and Subsequent HighlightsRevenue for Q3’23 increased 22% to $14.7 million, compared to revenue of $12.1 million for Q3’22.Security segment revenues increased 36% to $9.0 million in Q3’23 as border protection vertical drives new order volumes for Vicon.Gross margin up 200 basis points to 44% in Q3’23 from 42% in the prior year quarter Operating...

Revenue up 370% from Q2 2022 Gross profit up 691% from Q2 2022 Operating Expenses up 122% from Q2 2022 Positive adjusted EBITDAMINNETONKA, Minn., Aug. 10, 2023 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the second quarter ended June 30, 2023. Pineapple CEO Kyle Udseth commented, “We were able to deliver an excellent second quarter, against a backdrop of uncertainty in the residential solar industry and counter to the weak results turned in by many of our larger public peers. This was not by accident. We kept the focus on execution and in our Hawaii and New York markets, while responsibly managing corporate overhead. Our strategy is proving out, as selective acquisitions of leading...

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and potentially transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “In the second quarter, we presented data from our second clinical program, TPST-1495, the company’s novel dual EP2/EP4 antagonist designed to selectively modulate the prostaglandin pathway, both at ASCO and in a paper published in Cancer Research Communications. These presentations were made on the heels of announcing early exciting triplet data from our lead TPST-1120...

Conference call and webcast on August 10, 2023 at 5 p.m. ET RADNOR, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Safeguard Scientifics, Inc. (NASDAQ:SFE) (“Safeguard” or the “Company”) today announced financial results for the three and six months ended June 30, 2023. SECOND QUARTER 2023 HIGHLIGHTSFinancial ResultsCash, cash equivalents and restricted cash totaled $15.1 million at June 30, 2023. The carrying value of the Company’s ownership interests totaled $13.0 million at June 30, 2023. The total cost of the Company’s ownership interests was $138.4 million. Net loss for the three months ended June 30, 2023 was $2.9 million, or $0.18 per share, as compared with a net income of $0.5 million, or $0.03 per share, for the same period in 2022. Net loss for the six months ended June 30, 2023 was $6.3 million, or $0.39 per share, as compared...

Record Fundraising and Deployment Drives Double-Digit Revenue Growth DALLAS, Aug. 10, 2023 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights:Fee Paying Assets Under Management: $22.2 billion, a 20% increase year over year. Revenue: $62.5 million, a 34% increase year over year. GAAP Net Income: $2.1 million, an 81% decrease year over year. Adjusted EBITDA: $34.8 million, a 35% increase year over year. Adjusted Net Income: $26.7 million, a 15% increase year over year. Fully diluted GAAP EPS: $.02, a 78% decrease year over year. Fully diluted ANI per share: $.22, a 16% increase year over year.A presentation of the quarterly financials may be accessed here and is available on...